🧬 The Algorithm Biotech Gold Rush: What I’m Watching (That Most VCs Aren’t)
Your Weekly Shortcut to Deeptech Investing — Trends, Startup Intel & Investor Playbooks for VCs & Angels in 5 Minutes or Less
Picture this: AI isn’t just helping scientists tweak medicines anymore—it’s inventing brand-new drugs all on its own! Startups are using super-smart computer programs to whip up antibodies—those tiny proteins that fight off sickness—and it’s turning biotech into a wild treasure hunt. MIT Tech Review (March 2025) says companies like Generate:Biomedicines and Absci are leading the pack, creating fresh molecules from scratch instead of fixing old ones.
Big money’s jumping in too—ever since some brainy ex-OpenAI’ers and DeepMind’ers started their own biotech companies in 2024, investors have been pouring cash into this space. It’s like a gold rush, but with code digging up cures that could make billions.
Let’s break it down so you can see why this is your big chance.
What’s Going On?
This is real stuff, not sci-fi. Normally, scientists spend years messing around in labs, testing drugs on mice and people, hoping something sticks—it’s slow and tough. But these startups? They’ve got AI programs—like the ones that power ChatGPT—crunching tons of info to design new antibodies in just weeks. MIT Tech Review says Generate:Biomedicines made dozens of new molecules in 2024 to fight diseases like Alzheimer’s. Absci cut the time to design proteins by 50% (Absci update, Feb 2025)—that’s twice as fast as the old way! These aren’t little tweaks; they’re totally new ideas humans might’ve missed. It’s like a chef getting a magic recipe book that writes itself.
Why’s Everyone Throwing Money At It?
The cash started flowing big time in 2024 when ex-OpenAI and DeepMind experts—guys who built AI to win at chess—jumped into biotech. PitchBook (Q1 2025) shows investors dumped $2.5 billion into these AI-first biotech startups last year—that’s 3 times more than before! Why? It could cut the cost of making a drug from $2 billion to under $500 million (Forbes, March 2025). Big shots like Google Ventures and SoftBank are pouring in $100 million rounds—like the one Inceptive Therapeutics got. Even Pfizer is betting big, testing AI-made antibodies that could pull in $200 million by 2027 if they work (Bloomberg, Feb 2025). That’s real cash, not just talk.
Who’s Buying This Stuff?
Big drug companies are already lining up. Generate:Biomedicines scored a $50 million deal with Amgen in 2024 to make antibodies for rare diseases—they’re shipping samples now (Crunchbase, Q1 2025). Absci locked in $30 million from Merck to speed up protein designs (Absci, Feb 2025). Pfizer’s got a $1.2 billion AI drug plan, aiming for $5 billion a year if their antibodies hit the market (PharmaExec, 2024). These aren’t just handshakes—real money’s changing hands, showing people want this tech bad.
What’s Making This Happen?
A few big things are driving this rush. First, we need new drugs fast—cancer, Alzheimer’s, and new bugs keep popping up, and old ways fail 9 out of 10 times (FDA, 2024). AI’s bumping that to 1 in 4 with smarter designs (Nature Biotech, Jan 2025). Second, governments are pitching in—the U.S.’s NIH and DARPA threw $500 million at AI biotech in 2025 (NIH Budget, March 2025) to speed it up. Third, the market’s giant—antibody drugs made $400 billion in 2024 and could double to $800 billion by 2030 (Statista, March 2025). That’s a massive cash waiting to be grabbed!
How Much Could You Make?
Here’s the fun part—what’s it worth? Generate:Biomedicines raised $370 million and sits at $1.5 billion now (Crunchbase, Q1 2025)—their $50M Amgen deal and patents back that up. Absci’s at $800 million with $200 million in funding (PitchBook, Q1 2025), thanks to Merck’s $30M. Put in $1 million today, and if they hit big, you could see $5 million to $10 million by 2030—Pfizer might even buy one for $5 billion in 2028. That’s not a wild guess; it’s based on real sales and deals.
What Could Mess It Up—and How They Fix It
It’s not all easy. Drug approvals take 5-10 years (FDA, 2024), and if tests don’t work, startups burn $10 million a month. China’s putting $1 billion at their own AI biotech (CSIS, March 2025)—they could flood the market with cheap copies. But here’s the fix: Generate’s testing early with Amgen to catch flops fast, and Absci’s locking in $50M deals to keep cash coming. Smart moves like that keep them alive.
Your Next Step
This gold rush is your shot at the next biotech giants. Look for startups with AI making new drugs, lab proof like Generate’s molecules, and big buyers—Merck, Amgen, Pfizer. The market’s hot, and 2025-2027’s your window to jump in before everyone else catches on. A $1M bet now could hit $5M-$10M if they nail it. Stay in the loop—this is where the big money’s heading, and you’ve got the front-row seat.
📲 For behind-the-scenes insights, dealflow drops & deeptech trends in real time:
→ Follow @investdeeptech
→ Connect with me personally @eden_jana
Stay sharp,
Eden Djanashvili
Author, Invest Deeptech